The total return over the past 12 months is -75.64% vs. +16.94% for the S&P 500. So far it's up -67.59% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (75.64%) | (43.76%) | (61.00%) | N/A | N/A | N/A |
| Total Return CAGR | (75.64%) | (43.76%) | (61.00%) | N/A | N/A | N/A |
| Revenue CAGR | (67.27%) | (32.91%) | (31.68%) | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
BioNexus Gene Lab Corp. (BGLC)
| Year | Start price | End price | BGLC Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $3.95 | $1.28 | (67.59%) | +14.51% | (82.10%) |
| 2025 | $2.80 | $3.95 | +41.07% | +17.72% | +23.35% |
| 2024 | $5.30 | $2.80 | (47.17%) | +24.89% | (72.06%) |
| 2023 | $114.00 | $5.30 | (95.35%) | +26.19% | (121.54%) |
| 2022 | $255.70 | $114.00 | (55.42%) | (18.17%) | (37.25%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
